Genmab — Januar 2021
-
Endnu en "ægsbert" har nogle guldkorn
: https://ugebrev.dk/formue/markedskommentar/ubehageligt-hoej-risiko-for-bratte-kursfald/?mc_cid=9312e17db2&mc_eid=5805bdd5ee -
the new Ph3 Tisotumab innovaTV 301trial starts recruiting https://clinicaltrials.gov/ct2/history/NCT04697628?A=2&B=3&C=merged#StudyPageTop
-
the new Ph3 trial of Epcoritamab starts recruiting https://clinicaltrials.gov/ct2/history/NCT04628494?A=2&B=3&C=merged#StudyPageTop
-
Så er der bestilt nu skærm til PC'en. Den gamle har fået knas med farverne, så den kun viser rødt
-
-
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement Copenhagen, Denmark; January 27, 2021 – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons. This company announcement reflects the vesting and net settlement of the remaining part of the restricted stock units granted to Jan van de Winkel and Judith Klimovsky on December 15, 2017. The remaining part of these two grants has vested upon confirmation of vesting criteria linked thereto. About Genmab Genmab is an international biotechnology company with a core purpose to improve the lives of patients with cancer. Founded in 1999, Genmab is the creator of multiple approved antibody therapeutics that are marketed by its partners. The company aims to create, develop and commercialize differentiated therapies by leveraging next-generation antibody technologies, expertise in antibody biology, translational research and data sciences and strategic partnerships. To create novel therapies, Genmab utilizes its next-generation antibody technologies, which are the result of its collaborative company culture and a deep passion for innovation. Genmab’s proprietary pipeline consists of modified antibody candidates, including bispecific T-cell engagers and next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. The company is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com. Contact: Marisol Peron, Senior Vice President, Global Investor Relations & CommunicationsT: +1 609 524 0065; E: [email protected] For Investor Relations: Andrew Carlsen, Senior Director, Head of Investor RelationsT: +45 3377 9558; E: [email protected] This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody®; HexElect®; and UniBody®. CVR no. 2102 3884LEI Code 529900MTJPDPE4MHJ122 Genmab A/SKalvebod Brygge 431560 Copenhagen VDenmark Attachment 270121_CA05_RSU_Vesting
Yahoo Finance (finance.yahoo.com)
-
The Hubrecht Institute and Genmab have developed a new robot, the STRIP-1 – test robot, that can process up to 20,000 samples for SARS-CoV-2 testing per 24 hours. https://www.hubrecht.eu/strip-1-test-robot-for-covid-19-testing/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind